The Gut Microbiome and Ferroptosis in MAFLD

Area of Science:

• Hepatology and Gastroenterology
• Cellular Biology
• Microbiology

Background:

• Metabolic-associated fatty liver disease (MAFLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most prevalent liver condition globally.
• MAFLD/NAFLD pathogenesis involves insulin resistance, genetic factors, and metabolic stress.
• The gut-liver axis highlights the reciprocal relationship between gut microbiota and liver health.

Purpose of the Study:

• To review the mechanisms by which gut microbiota and ferroptosis contribute to MAFLD/NAFLD development.
• To explore novel therapeutic strategies targeting the gut microbiota and ferroptosis for MAFLD/NAFLD.

Main Methods:

• Literature review focusing on the roles of intestinal microbiota and ferroptosis in MAFLD/NAFLD.
• Analysis of emerging evidence on ferroptosis as a programmed cell death pathway in liver injury.
• Examination of the gut-liver axis in the context of metabolic liver disease.

Main Results:

• Gut microbiota significantly influences the occurrence and progression of MAFLD/NAFLD.
• Ferroptosis, an iron-dependent cell death, plays a critical role in MAFLD/NAFLD pathology.
• Inhibiting ferroptosis presents a potential therapeutic avenue for MAFLD/NAFLD.

Conclusions:

• Understanding the interplay between gut microbiota and ferroptosis is crucial for MAFLD/NAFLD.
• Targeting these pathways offers promising strategies for future MAFLD/NAFLD therapies.
• The re-evaluation of gut microbiota in MAFLD/NAFLD underscores its systemic impact.